Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

NOXCOVID Trial Advances to Final Stage (ASX:NOX)

Positive review of hospitalized COVID-19 patients triggers approval to move from Part 1 to Part 2 of the trial Top dose of 1800 mg Veyonda daily to be used in final patient cohort Tests on blood ...read more

Noxopharm: Updated Corporate Presentation February-March 2021 (ASX:NOX)

Australian clinical stage drug development company, Noxopharm Limited (ASX:NOX), provides to shareholders and the market generally the attached corporate presentation ahead of a series of global vir...read more

Nyrada Reports Half Year FY2021 Results (ASX:NYR)

To view the report, download the attached PDF.

Noxopharm Announces LuPIN Trial Survival Outcome Confirmed by Conference Presentation (ASX:NOX)

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to provide a more detailed summary of the data from the LuPIN study that was formally presented to the Ameri...read more

Noxopharm Announces Global Conference To Hear of Major Survival Benefit in Prostate Cancer Patients (ASX:NOX)

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to report the publication in abstract form of the latest survival data from the LuPIN study ahead of a forma...read more

Nyrada Reports Further Results from Cholesterol Study (ASX:NYR)

Nyrada Inc (ASX: NYR) is pleased to report new additional exploratory results of its in vivo cholesterol efficacy study, first announced on 21 December 2020. The study used a mouse model that has be...read more

Novatti Visa Prepaid card now supported by Apple Pay (ASX:NOV)

Novatti Group Limited (ASX:NOV) (Novatti or Company), a leading digital banking and payments company, is pleased to announce that its Visa Prepaid cards are now supported by Apple Pay. This will ...read more

Noxopharm Announces NOXCOVID Study Advances (ASX:NOX)

Australian clinical stage drug development company, Noxopharm Limited (ASX:NOX), announces that the latest formal review by the NOXCOVID-1 Safety Steering Committee has cleared it to advance to the ...read more

Noxopharm Shareholder Update 2021 (ASX:NOX)

Australian clinical stage drug development company, Noxopharm Limited (ASX:NOX), provides this shareholder update as a summary of R&D progress in 2020 and a guide to what 2021 is expected to hol...read more

57% Reduction in Total Cholesterol from Nyradas NYX-PCSK9i In Vivo Study (ASX:NYR)

Nyrada Inc (ASX: NYR) is pleased to report encouraging efficacy results from its cholesterol-lowering drug program which is directed at developing an oral PCSK9 inhibitor treatment for hypercholestero...read more

Noxopharm Announces PreClinical Breakthrough Discovery Set to Expand Noxopharm Pipeline (ASX:NOX)

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce what it regards as a major breakthrough in anti-cancer drug discovery. Noxopharm scientists h...read more

Novatti Group - Ripple partnership to fast-track growth in South-East Asia (ASX:NOV)

Novatti Group Limited (ASX:NOV) (Novatti or Company), a leading digital banking and payments company, has formed a major new partnership with global payments disrupter, Ripple, to target the rapidly...read more

Noxopharm Completes A$23 million Placement to Fund Clinical Studies (ASX:NOX)

Highlights: - Noxopharm successfully raises A$23 million via a Placement, with cornerstone institutional investors coming from Australia, Hong Kong and the USA - Funds raised will drive two new ...read more

Noxopharm - Independent Discovery Validates DARRT Cancer Therapy (ASX:NOX)

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to note that a recent discovery by a major U.S. university group significantly validates the Company’s...read more

Noxopharm - Veyonda To Be Tested In Combination With Opdivo In Trial (ASX:NOX)

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce that NOX have joined with Principal Investigator, Professor Paul De Souza, and three Sydney hosp...read more

Viewing: 1 - 15 of 200 Previous | Next